<DOC>
	<DOCNO>NCT01676220</DOCNO>
	<brief_summary>Primary Objective : To compare efficacy new formulation insulin glargine Lantus term change HbA1c baseline endpoint ( schedule Month 6 , Week 26 ) participant type 2 diabetes mellitus Secondary Objectives : To compare new formulation insulin glargine Lantus term : - occurrence nocturnal hypoglycemia</brief_summary>
	<brief_title>Comparison New Formulation Insulin Glargine With Lantus Patients With Type 2 Diabetes Non-insulin Antidiabetic Therapy</brief_title>
	<detailed_description>The maximum study duration approximately 54 week per participant , consist : - Up 2 week screening period ; exceptionally extend one additional week - 6-month comparative efficacy safety treatment period - 6-month comparative safety extension period - 2-day post-treatment safety follow-up period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Adult participant type 2 diabetes mellitus inadequately control noninsulin antihyperglycemic drug ( ) ; Signed write informed consent . Exclusion criterion : HbA1c le ( &lt; ) 7.0 % ( &lt; 53 millimole per mole [ mmol/mol ] ) great ( &gt; ) 11 % ( &gt; 97 mmol/mol ) History type 2 diabetes mellitus less 1 year screen Less 6 month screen noninsulin antihyperglycemic treatment Change dose noninsulin antihyperglycemic treatment last 3 month screen Initiation new glucoselowering medication and/or weight loss drug last 3 month screen visit and/or initiation Glucagonlike peptide1 ( GLP1 ) receptor agonist last 6 month screen visit Participants receive noninsulin antihyperglycemic drug approve combination insulin accord local labeling/local treatment guideline and/or sulfonylurea glinide ( Note : noninsulin antihyperglycemic drug approve combination insulin , sulfonylurea glinide discontinue baseline ) Current previous insulin use except maximum 8 consecutive day ( example , acute illness , surgery ) last year prior screen Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( example , laser , surgical treatment injectable drug ) study period The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>